2023
Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020
Li D, Laine L, Shung D. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. The American Journal Of Medicine 2023, 136: 1179-1186.e1. PMID: 37696350, PMCID: PMC10841721, DOI: 10.1016/j.amjmed.2023.08.010.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingGastrointestinal bleedingRed blood cell transfusionNationwide Emergency Department SamplePrimary cardiovascular preventionRecent guideline recommendationsBlood cell transfusionProportion of hospitalizationsEmergency Department SampleMedicare reimbursementInternational Statistical ClassificationRelated Health ProblemsCardiovascular preventionCell transfusionOlder patientsHospital admissionCommon etiologyGuideline recommendationsMajor complicationsUlcer diseaseEndoscopic interventionRevision codesAppropriate indicationsRecent guidelinesCardiovascular disease
2022
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAgedAged, 80 and overAspirinCardiovascular DiseasesGastrointestinal HemorrhageHumansMiddle AgedPatient DischargePrimary PreventionConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPrevention
2019
Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group.
Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, Leontiadis GI, Abraham NS, Calvet X, Chan FKL, Douketis J, Enns R, Gralnek IM, Jairath V, Jensen D, Lau J, Lip GYH, Loffroy R, Maluf-Filho F, Meltzer AC, Reddy N, Saltzman JR, Marshall JK, Bardou M. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Annals Of Internal Medicine 2019, 171: 805-822. PMID: 31634917, PMCID: PMC7233308, DOI: 10.7326/m19-1795.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUpper gastrointestinal bleedingNonvariceal upper gastrointestinal bleedingHigh-risk stigmataPPI therapyGastrointestinal bleedingEndoscopic therapyCardiovascular diseaseHigh-dose proton pump inhibitor therapyEvidence profilesProton pump inhibitor therapyGlasgow-Blatchford scoreOral PPI therapyPrevious ulcer bleedingHigh-risk patientsHours of presentationManagement of patientsSuccessful endoscopic therapyStrength of recommendationsQuality of evidenceInternational consensus recommendationsInternational multidisciplinary groupInternational Consensus GroupElectronic bibliographic databasesTC-325Blatchford score
2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal Of Rheumatology 2011, 38: 1071-8. PMID: 21459935, DOI: 10.3899/jrheum.100880.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidBiomarkersCardiovascular DiseasesC-Reactive ProteinDiclofenacEtoricoxibFemaleHeart FailureHumansLongitudinal StudiesMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainOsteoarthritisPeptide FragmentsProspective StudiesPyridinesRetrospective StudiesRisk FactorsSulfonesThrombosisTreatment OutcomeConceptsHigh-sensitivity C-reactive proteinNonsteroidal antiinflammatory drugsSensitivity C-reactive proteinNT-proBNPC-reactive proteinHeart failureCV eventsCV outcomesCV riskThrombotic eventsMyocardial infarctionAntiinflammatory drugsBiomarkers N-terminal pro-B-type natriuretic peptideCardiac biomarkers N-terminal pro-B-type natriuretic peptideN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic nonsteroidal antiinflammatory drugsBaseline NT-proBNPChronic NSAID treatmentLow CV riskNT-proBNP levelsFuture cardiovascular eventsBody mass indexIdentification of patientsTypes of arthritis
2010
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal Of Gastroenterology 2010, 105: 2533. PMID: 21131924, DOI: 10.1038/ajg.2010.445.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnti-Inflammatory Agents, Non-SteroidalAryl Hydrocarbon HydroxylasesAspirinCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C19Drug InteractionsDrug Therapy, CombinationGastrointestinal HemorrhageHistamine H2 AntagonistsHumansPiperazinesPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRisk FactorsThienopyridinesThiophenesTiclopidineACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Members W, Abraham N, Hlatky M, Antman E, Bhatt D, Bjorkman D, Clark C, Furberg C, Johnson D, Kahi C, Laine L, Mahaffey K, Quigley E, Scheiman J, Sperling L, Tomaselli G. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 2010, 122: 2619-2633. PMID: 21060077, DOI: 10.1161/cir.0b013e318202f701.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnti-Inflammatory Agents, Non-SteroidalAryl Hydrocarbon HydroxylasesAspirinCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C19Drug InteractionsDrug Therapy, CombinationGastrointestinal HemorrhageHistamine H2 AntagonistsHumansPiperazinesPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRisk FactorsThienopyridinesThiophenesTiclopidineClopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal Of Medicine 2010, 363: 1909-1917. PMID: 20925534, DOI: 10.1056/nejmoa1007964.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsDual antiplatelet therapyUpper gastrointestinal bleedingAntiplatelet therapyCardiovascular eventsGastrointestinal bleedingOvert upper gastrointestinal bleedingPrimary cardiovascular end pointEnd pointEvent ratesEfficacy of clopidogrelSymptomatic gastroduodenal ulcersCardiovascular end pointsComposite of deathNonfatal myocardial infarctionSerious adverse eventsCoronary artery diseaseHigh-risk subgroupsRisk of diarrheaCardiovascular causesGastrointestinal complicationsGastrointestinal eventsOccult bleedingAntithrombotic therapyAdverse events
2009
Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?
Laine L, Hennekens C. Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction? The American Journal Of Gastroenterology 2009, 105: ajg2009638. PMID: 19904241, DOI: 10.1038/ajg.2009.638.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsClopidogrel usersCV eventsClopidogrel efficacyPump inhibitorsObservational studyPresence of PPIsTrial of omeprazoleHealth care providersCytochrome P450Clopidogrel actionClopidogrel interactionCardiovascular eventsGastrointestinal bleedingRandomized trialsConcomitant useSurrogate markerRecommendations stateClopidogrelCurrent evidenceCYP2C19 functionUS FoodDrug AdministrationPlatelet aggregationActive metaboliteCardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009, 48: 425-432. PMID: 19223284, DOI: 10.1093/rheumatology/kep005.Peer-Reviewed Original ResearchConceptsThrombotic CV eventsHazard ratioCV eventsBlood pressureEfficacy parametersMaximum average changeAdverse event discontinuation rateDouble-blind studyMean treatment durationCohort of patientsSystolic blood pressureEtoricoxib 60Cardiovascular safetyGastrointestinal tolerabilityPrimary endpointRA cohortRA patientsTolerability profileAverage changeDiscontinuation ratesOA patientsPatient cohortClinical trialsSimilar efficacyTreatment duration
2008
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal Of Gastroenterology 2008, 103: ajg2008576. PMID: 18853980, DOI: 10.1111/j.1572-0241.2008.02200.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalCardiovascular DiseasesGastrointestinal DiseasesHumansPlatelet Aggregation InhibitorsConceptsNonselective nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsGI risk factorsNonsteroidal anti-inflammatory drugsCV riskHigh CV riskProton pump inhibitorsAnti-inflammatory drugsRisk factorsCyclooxygenase-2- selective nonsteroidal antiinflammatory drugsSelective nonsteroidal antiinflammatory drugsCardiovascular safety issuesMultidisciplinary international panelPatient's CV riskClinical practice recommendationsManagement of patientsAnti-platelet agentsGI complicationsCardiovascular effectsGI riskInternational working partyPump inhibitorsTreatment strategiesAntiinflammatory drugsPatients
2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, Committee F. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 2006, 368: 1771-1781. PMID: 17113426, DOI: 10.1016/s0140-6736(06)69666-9.Peer-Reviewed Original ResearchConceptsThrombotic cardiovascular eventsNon-steroidal anti-inflammatory drugsCardiovascular eventsHazard ratioRheumatoid arthritisCyclo-oxygenase-2 (COX-2) selective inhibitorsTraditional non-steroidal anti-inflammatory drugsCOX-2 selective inhibitorsPrespecified pooled analysisRelative cardiovascular riskTraditional NSAID diclofenacUpper gastrointestinal eventsPlacebo-controlled trialAverage treatment durationAnti-inflammatory drugsSelective inhibitorLong-term useDiclofenac groupEtoricoxib groupGastrointestinal eventsMultinational EtoricoxibCardiovascular outcomesCardiovascular riskTreat analysisClinical eventsReview article: gastrointestinal bleeding with low‐dose aspirin – what's the risk?
LAINE L. Review article: gastrointestinal bleeding with low‐dose aspirin – what's the risk? Alimentary Pharmacology & Therapeutics 2006, 24: 897-908. PMID: 16948802, DOI: 10.1111/j.1365-2036.2006.03077.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLow-dose aspirinGastrointestinal bleedingPlacebo-controlled trialRelative riskNon-aspirin non-steroidal anti-inflammatory drugsLarge Danish cohort studyRandomized placebo-controlled trialNon-steroidal anti-inflammatory drugsAbsolute annual incidenceDanish cohort studyMajor gastrointestinal bleedingUpper gastrointestinal bleedingEnteric-coated aspirinAbsolute rate increaseAnti-inflammatory drugsEndoscopic trialsCorticosteroid useAnticoagulant therapyCardiovascular benefitsCohort studyAnnual incidenceVascular protectionClinical eventsUlcer incidenceOdds ratio
2004
Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy
Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy. Alimentary Pharmacology & Therapeutics 2004, 19: 197-208. PMID: 14723611, DOI: 10.1111/j.0269-2813.2004.01834.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsCost of NSAIDsPump inhibitorsGastrointestinal eventsChronic anti-inflammatory therapyRAND/UCLA Appropriateness MethodNon-steroidal anti-inflammatory drugsAnti-inflammatory therapyAnti-inflammatory drugsDrug treatment strategiesCommunity-based settingsCardiovascular riskProphylactic useAppropriateness MethodTreatment strategiesLower riskNSAIDsPatientsClinical scenariosAspirinAppropriate useInhibitorsRiskCare entitiesLiterature review
2000
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M, Hawkey C, Hochberg M, Kvien T, Schnitzer T. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal Of Medicine 2000, 343: 1520-1528. PMID: 11087881, DOI: 10.1056/nejm200011233432103.Peer-Reviewed Original ResearchMeSH KeywordsAdultArthritis, RheumatoidCardiovascular DiseasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDuodenal ObstructionFemaleGastric Outlet ObstructionGastrointestinal DiseasesGastrointestinal HemorrhageHumansIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedNaproxenPeptic UlcerProportional Hazards ModelsProstaglandin-Endoperoxide SynthasesSulfonesConceptsUpper gastrointestinal eventsNonselective nonsteroidal antiinflammatory drugsGastrointestinal eventsRheumatoid arthritisCyclooxygenase-2Upper gastrointestinal toxicityPercent of patientsPrimary end pointOverall mortality rateNonsteroidal antiinflammatory drugsRate of deathYears of ageNonselective NSAID naproxenSelective inhibitorCardiovascular causesRofecoxib groupGastrointestinal toxicityNaproxen groupMyocardial infarctionSimilar efficacyAntiinflammatory drugsLower incidenceArthritisMortality ratePatients